Agilent pd-l1 ihc 22c3 pharmdx receives expanded fda approval in non-small cell lung cancer (nsclc)

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced that the u.s. food and drug administration (fda) has approved the company's pd-l1 ihc 22c3 pharmdx assay for expanded use in patients with non-small cell lung cancer (nsclc). pd-l1 ihc 22c3 pharmdx can now be used as an aid in identifying nsclc patients with tumor pd-l1 expression of tumor proportion score (tps) ≥ 50% for treatment with libtayo® (cemiplimab-rwlc). this announcement underscores agilent's co
A Ratings Summary
A Quant Ranking